Researchers at two UK sites gave 73 people with Long COVID a five-day course of intravenous remdesivir. 97% completed the full regimen with no severe adverse reactions. Exploratory outcomes showed improvements in fatigue and physical performance, but the authors stress the study was open-label and not placebo-controlled, and that large randomised controlled trials are needed to determine real efficacy.